Blood Based Biomarker Market, By Type (Screening Biomarker, Diagnosis Biomarker, and Others), By Disease (Cancer, Neurological Disorders, and Others), By Application (Diagnostics, Drug Discovery, and Personalized Medicine), and By Region (North America, L

Blood Based Biomarker Market, By Type (Screening Biomarker, Diagnosis Biomarker, and Others), By Disease (Cancer, Neurological Disorders, and Others), By Application (Diagnostics, Drug Discovery, and Personalized Medicine), and By Region (North America, Latin America, Europe, Asia-Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

The term biomarker, or biological marker, refers to a broad range of measures that capture what is happening in a cell or organism at a given moment. Blood-based biomarkers can be effective in formulating new diagnostic and treatment proposals. Blood-based biomarkers have significant advantages of being time and cost-efficient
Market Dynamics
Key players operating in the global blood based biomarker market are focusing on adoption of growth strategies such as product launch, collaboration, and fund raise which are expected to drive the market growth during the forecast period. For instance, in September 2020, ONCOtracker, Inc., a West Hollywood-based oncology company and The Binding Site Group Ltd, provides specialist diagnostic products to clinicians and laboratory professionals worldwide, announced they have entered into an exclusive global license and collaboration agreement to develop a novel clinical laboratory test for measuring sBCMA, a novel blood-based biomarker, which has shown promise to monitor and predict outcomes for patients with common blood-based cancers including multiple myeloma (MM) and chronic lymphocytic leukemia (CLL) and other related conditions. Moreover, for instance, in April 2021, Sera Prognostics, a Women’s health company had secured US$100 m in Series E financing to advance the commercialization of its PreTRM test for premature birth risk. The PreTRM test is a clinically validated and commercially available blood-based biomarker test, which offers an early, precise, and individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies.
Key features of the study:
This report provides an in-depth analysis of the Global Blood Based Biomarker Market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global blood based biomarker market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
Key companies covered as a part of this study include Diadem srl., Proteomedix, Cleveland Diagnostics, F. Hoffmann-La Roche Ltd, GENFIT, Nutech Cancer Biomarkers India Pvt Ltd, SysmOex Corporation, Minomic, Creative Diagnostics, Eisai Co., Ltd., and C2N Diagnostics
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global blood based biomarker market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global blood based biomarker market
Detailed Segmentation:
Global Blood Based Biomarker Market, By Type :
Screening Biomarker
Diagnosis Biomarker
Others
Global Blood Based Biomarker Market, By Disease :
Cancer
Neurological Disorders
Others
Global Blood Based Biomarker Market, By Application :
Diagnostics
Drug Discovery
Personalized Medicine
Global Blood Based Biomarker Market, By Region:
North America
By Type
Screening Biomarker
Diagnosis Biomarker
Others
By Disease
Cancer
Neurological Disorder
Others
By Application
Diagnostics
Drug Discovery
Personalized Medicine
By Country
U.S.
Canada
Latin America
By Type
Screening Biomarker
Diagnosis Biomarker
Others
By Disease
Cancer
Neurological Disorder
Others
By Application
Diagnostics
Drug Discovery
Personalized Medicine
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Type
Screening Biomarker
Diagnosis Biomarker
Others
By Disease
Cancer
Neurological Disorder
Others
By Application
Diagnostics
Drug Discovery
Personalized Medicine
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Type
Screening Biomarker
Diagnosis Biomarker
Others
By Disease
Cancer
Neurological Disorder
Others
By Application
Diagnostics
Drug Discovery
Personalized Medicine
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Type
Screening Biomarker
Diagnosis Biomarker
Others
By Disease
Cancer
Neurological Disorder
Others
By Application
Diagnostics
Drug Discovery
Personalized Medicine
By Country
GCC
Israel
Rest of Middle East
Africa
By Type
Screening Biomarker
Diagnosis Biomarker
Others
By Disease
Cancer
Neurological Disorder
Others
By Application
Diagnostics
Drug Discovery
Personalized Medicine
By Country
South Africa
Central Africa
North Africa
Company Profiles
Diadem srl.*
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Strategies
Proteomedix
Cleveland Diagnostics
F. Hoffmann-La Roche Ltd
GENFIT
Nutech Cancer Biomarkers India Pvt Ltd
SysmOex Corporation
Minomic
Creative Diagnostics
Eisai Co., Ltd.
C2N Diagnostics
“*” marked represents similar segmentation in other categories in the respective section.